Small Molecule TNF Inhibitors for Soluble Biologic Alternatives
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunomodulatory biologics targeting TNF superfamily costimulatory interactions face challenges such as solubility issues, stability problems, and adverse reactions, limiting their effectiveness in treating autoimmune diseases and transplant-related conditions.
Innovation Solution
Development of small molecule compounds, specifically those of Formula (I), which modulate TNF superfamily costimulatory interactions by inhibiting proteins like CD40-CD40L, offering improved potency and reduced adverse effects compared to traditional biologics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If biologics are used to block TNF superfamily costimulatory interactions, then immune modulation efficacy is improved, but solubility and stability problems occur
Solution Approach 1:
The patent changes the molecular form from biologic (protein/antibody) to small molecule compound, fundamentally altering physical and chemical parameters such as solubility, stability, and pharmacokinetic properties while maintaining the ability to block costimulatory interactions
Solution Approach 2:
The small molecule compounds replicate the immunomodulatory function of biologics by blocking the same costimulatory interactions (CD40-CD40L, OX40-OX40L, etc.) but through a different molecular mechanism, effectively creating a functional copy with improved physical properties
2Reliability
If biologics are used to block TNF superfamily costimulatory interactions, then immune modulation efficacy is improved, but adverse reactions increase
Solution Approach 1:
The patent changes the molecular form from biologic (protein/antibody) to small molecule compound, fundamentally altering molecular size, structure, and pharmacokinetic parameters while maintaining the ability to block costimulatory interactions
Solution Approach 2:
The small molecule compounds replicate the immunomodulatory function of biologics by blocking the same costimulatory interactions (CD40-CD40L, OX40-OX40L, etc.) but through a different molecular mechanism, effectively creating a functional copy with improved safety profile
3Measurement precision
If small molecule compounds are used to inhibit TNF superfamily costimulatory interactions, then binding affinity is improved, but molecular complexity increases
Solution Approach 1:
The patent optimizes specific molecular parameters of the small molecule compounds, including substituent groups (R1, R2, R), ring structures (n, m), and linker configurations, to enhance binding affinity to costimulatory molecules while managing structural complexity
Data Source
Figure 1A~1B
Figure 2~3
Figure 4~5
AI summary
Disclosed herein are inhibitors of TNF superfamily costimulatory interactions, and methods for their use in modulating TNF superfamily costimulatory interactions and treating immune system related disorders. In particular, disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof: wherein the substituents are described herein.